A Randomized, Double-Blind, Placebo-Controlled Phase 4 Clinical Trial to Evaluate the Long-Term Safety and Efficacy of Avacopan in Subjects with Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis

Principal Investigator

Elizabeth Brant

Study Number

STUDY02002531

Summary

The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Phase

IV

Available at the following location(s)

• Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms